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Abstract
Background: 18-Fluorodeoxyglucose-PET (
18F-FDG-PET) can be used for early response assessment in patients with
locally advanced adenocarcinomas of the oesophagogastric junction (AEG) undergoing neoadjuvant chemotherapy.
It has been recently shown in the MUNICON trials that response-guided treatment algorithms based on early
changes of the FDG tumor uptake detected by PET are feasible and that they can be implemented into clinical
practice.
Only 40%-50% of the patients respond metabolically to therapy. As metabolic non-response is known to be
associated with a dismal prognosis, metabolic non-responders are increasingly treated with alternative neoadjuvant
chemotherapies or chemoradiation in order to improve their clinical outcome. We plan to investigate whether PET
can be used as response assessment during radiochemotherapy given as salvage treatment in early metabolic non-
responders to standard chemotherapy.
Methods/Design: The HICON trial is a prospective, non-randomized, explorative imaging study evaluating the
value of PET as a predictor of histopathological response in metabolic non-responders. Patients with resectable
AEG type I and II according to Siewerts classification, staged cT3/4 and/or cN+ and cM0 by endoscopic ultrasound,
spiral CT or MRI and FDG-PET are eligible. Tumors must be potentially R0 resectable and must have a sufficient
FDG-baseline uptake. Only metabolic non-responders, showing a < 35% decrease of SUV two weeks after the start
of neoadjuvant chemotherapy are eligible for the study and are taken to intensified taxane-based RCT
(chemoradiotherapy (45 Gy) before surgery.
18FDG-PET scans will be performed before ( = Baseline) and after 14
days of standard neoadjuvant therapy as well as after the first cycle of salvage docetaxel/cisplatin chemotherapy
(PET 1) and at the end of radiochemotherapy (PET2). Tracer uptake will be assessed semiquantitatively using
standardized uptake values (SUV). The percentage difference ΔSUV = 100 (SUVBaseline - SUV PET1)/SUVBaseline will be
calculated and assessed as an early predictor of histopathological response. In a secondary analysis, the association
between the difference SUVPET1 - SUVPET2 and histopathological response will be evaluated.
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reproduction in any medium, provided the original work is properly cited.Discussion: The aim of this study is to investigate the potential of sequential
18FDG-PET in predicting
histopathological response in AEG tumors to salvage neoadjuvant radiochemotherapy in patients who do not
show metabolic response to standard neoadjuvant chemotherapy.
Trial Registration: Clinical trial identifier NCT01271322
Background
Oesophageal cancer is among the 10 most common
malignancies worldwide and is associated with a high
mortality [1,2]. Often, the tumors are locally advanced
at the time of initial diagnosis because symptoms do not
appear until late (T3-T4, N+, or M1). In cases of locally
advanced tumors (T3/T4, N+), surgery remains the
mainstay of therapy, but evidence is growing that preo-
perative chemotherapy or chemoradiotherapy improves
survival in responding patients with locally advanced
adenocarcinoma of the oesophagus and the oesophago-
gastric junction [3,4]. However, for patients who do not
respond, the prognosis after neoadjuvant therapy might
be worse than that of a primarily surgical approach [5].
These metabolic non-responders have a low histopatho-
logical response rate of only 5% and a poor prognosis
compared with responders [6]. Since about half of the
patients treated with neoadjuvant chemotherapy will not
respond [7], an early predictor of response would avoid
futile therapy and allow patients to pursue other, poten-
tially more efficacious treatments. Therefore, an indivi-
dual early assessment of response to neoadjuvant
therapy using imaging techniques could be of great
value for tailoring neoadjuvant treatment as well as the
surgical approach to the individual patient [8-10]. Over
the past few years, many attempts have been made to
improve prognostication of the individual tumor biology
in oesophageal carcinoma and to identify prognostic and
predictive biomarkers.
Metabolic changes measured by PET have been shown to
be more sensitive in detecting response early in the course
of chemotherapy as compared with both conventional ima-
ging techniques (EUS and CT) and endoscopy [11]. Various
studies have demonstrated that 18-fluorodeoxyglucose-
positron emission tomography (FDG-PET), measuring
early changes in tumor glucose uptake after only two weeks
of induction therapy, is a promising tool in the prediction
of clinical and histopathologic response as well as prognosis
to neoadjuvant treatment in adenocarcinomas of the oeso-
phagogastric junction (AEG) type I and II [6,12]. Available
evidence suggests that metabolic response might be a useful
predictive marker for the early identification of non-
responding patients. The MUNICON-I trial prospectively
showed that early metabolic assessment with therapy strati-
fication after only 2 weeks helps to select patients who are
not benefiting from neoadjuvant chemotherapy and can
therefore avoid ineffective and toxic therapy in non-
responding patients with AEG I and II [8,9]. These patients
with poor prognosis and potentially biologically even more
aggressive tumors might be suitable candidates for intensifi-
cation of the neoadjuvant treatment, by changing the
chemotherapeutic regimen in attempting to overcome che-
moresistance, and by adding radiochemotherapy.
Evidence in the literature gives the rationale to use a
taxane-based regimen in patients who are not responding
to a first line EOX/EOF (Epirubicin, Oxaliplatin, Capeci-
tabin/5-Fluorouracil) induction therapy [13]. A phase II
trial showed that Docetaxel given with Cisplatin is a
highly active chemotherapy schedule and permitted sur-
gery in initially inoperable patients [14]. Furthermore,
neoadjuvant chemoradiotherapy for adenocarcinoma of
the oesophagus seems to improve overall survival [4] and
may induce significantly higher response rates compared
to chemotherapy alone [15].
The primary objective of the Heidelberg Imaging pro-
gram in Cancer of the Oesophago-gastric junction during
Neoadjuvant treatment (HICON) trial is to investigate
whether semiquantitative measurements of
18F-FDG accu-
mulation at the primary tumor site using (sequential) PET
could be applied to assess the effects of salvage neoadju-
vant radiochemotherapy in initially non-responding
tumors, with metabolic response defined by a ≥35%
decrease in
18F-FDG uptake two weeks after induction
chemotherapy [6,12], using histopathology as a gold
standard.
Methods/Design
Study Design
HICON is a prospective, non-randomized, exploratory
imaging/biomarker study. The study is designed and coor-
dinated by the National Center for Tumor Disease (NCT),
Heidelberg. The protocol of the study was approved by
the local Ethics Committee, and was also subject to
authorization by the German radiation protection author-
ity (Bundesamt für Strahlenschutz = BfS) as mandatory by
federal law.
All participants provide written informed consent.
The study was assigned the number NCT01271322 in
the European Clinical Trials Database (EudraCT).
Study objectives and endpoints
T h ep r i m a r yo b j e c t i v eo ft h es t u d yi st oe v a l u a t et h e
change in metabolic response as measured by the relative
difference ΔSUV = 100 (SUVBaseline -S U V PET1)/SUVBaseline
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18F-FDG uptake after 1 cycle of salvage taxan-based
chemotherapy (PET1), relative to the
18F-FDG uptake at
the baseline examination, as a predictor of histopathologi-
cal response in initial metabolic non-responders (assessed
by PET 14 days after the start of neoadjuvant therapy).
Secondary objectives are the investigation of the distribu-
tion of ΔSUV in histological responders and non-respon-
ders, the accuracy of the binary prediction rule ΔSUV
≥65% vs. < 65% (in particular the question whether this
rule is superior to a random prediction), the association of
SUV measured by PET1 with the value of PET response
after intensified neoadjuvant radiochemotherapy (PET2),
the association between SUVPET1 -S U V PET2 and histo-
pathological response, and the association between ΔSUV
and overall survival as well as disease-free survival
(counted from the date of recruitment).
Patient selection
Eligibility criteria include the presence of biopsy-proven
adenocarcinoma of the distal oesophagus (AEG type I) or
cardia (AEG type II) [16], staged as cT3 or cT4, with or
without metastases in local lymph nodes and no evidence
of hematogenous metastases. Staging procedures include
endoscopy, endoscopic ultrasound and computed tomo-
graphy (CT) of the chest and abdomen. Eligible patients
have to be fit for platin-containing chemotherapy and
tumors must be potentially R0 resectable during conse-
cutive operation.
Tumors must have demonstrated a minimal amount
of FDG-uptake in the baseline PET-CT, defined as
18FDG-uptake in tumor at first examination > 1,35 ×
hepatic-SUV + 2 × standard-deviation of hepatic-SUV,
and must be a metabolic non-responder under EOX,
defined as a decrease of the SUVmax of < 35% in a sec-
ond PET on day 14 of chemotherapy.
Patients with an Eastern Cooperative Oncology Group
score worse than 1, previous or secondary malignancy,
life expectancy of less than 3 months, uncontrolled
bleeding from the tumor, tumor infiltration of the air-
ways, pregnancy, uncontrolled diabetes, or age less than
18 years are excluded. Patients are also ineligible if they
have undergone previous chemotherapy, radiotherapy,
or endoscopic laser therapy.
Treatment schedule/follow-up
After obtaining written informed consent, a baseline
FDG-PET will be performed during initial staging within
one week before initiation of preoperative chemother-
apy. Patients will be eligible for inclusion only if PET
scans show a sufficient contrast between tumor and sur-
rounding tissues: this is based on standard uptake value
(SUV) measurements. All eligible patients will be given
the following induction chemotherapy:
EOX: Epirubicin 50 mg/m
2 i.v. Bolus d1
Oxaliplatin 130 mg/m
2 i.v. d1
Capecitabin 2 × 625 mg/m
2 p.o. d1-21
Or (only if dysphagia):
EOF: Epirubicin 50 mg/m
2 i.v. Bolus d1
Oxaliplatin 130 mg/m
2 i.v. d1
5-FU 200 mg/m
2/d continuously i.v. d1-21
FDG-PET will be repeated on day 14 of the first
chemotherapy cycle
Patients whose tumor SUV will be decreased by ≥35%, will
be defined as metabolic responders. This cut-off is prede-
fined and is based on previous research [6,8,12]. Metabolic
responders will continue to receive chemotherapy for a
maximum of 12 weeks before surgery.
Metabolic non-responders, with a SUV decrease of
less than 35%, discontinue induction chemotherapy and
proceed to an intensified salvage radiochemotherapy
treatment, which forms the basis of the HICON study
(see Figure 1). Within this imaging/biomarker study,
patients will receive two more FDG-PET assessments to
evaluate metabolic response: the first right before the
onset of radiochemotherapy (PET1) and the second
after completion of radiochemotherapy and prior to
resection (PET2).
Within the HICON study, patients will be treated with
one cycle of chemotherapy with docetaxel 75 mg/m
2,
and cisplatin 75 mg/m
2 to allow radiation planning.
This treatment will be followed by radiochemotherapy,
starting on day 22 of intensified chemotherapy cycle:
Radiotherapy
1.8 Gy/day, total dose 45Gy
Docetaxel
25 mg/m
2 on days 1, 8, 15, 22, 29 of radiochemotherapy
(RCT) and Cisplatin: 25 mg/m
2 on days 1, 8, 15, 22, 29
of RCT. Docetaxel should be given before cisplatin.
C h e m o t h e r a p yi sg i v e no naw e e k l yb a s i s .C o m b i n e d
radiochemotherapy, with a total dose of 45Gy, is fol-
lowed by resection, 28 - 42 days after the end of RCT.
The protocol treatment ends 30 days post resection, or
if a longer hospital stay is needed, until the last day of
hospitalization.
After surgical resection, patients will be followed at 3-
month intervals by CT of the chest and abdomen and
upper intestinal endoscopy. In patients with curative
(R0) resection, time to recurrence will be calculated as
the time from initiation of neoadjuvant therapy to detec-
tion of local recurrence or distant metastases. In
patients with no resection or residual tumor after resec-
tion (R1 and R2 resection, respectively), time to tumor
progression will be determined.
The duration of the study is anticipated to be 15 months
(10 months accrual time plus 5 months of individual fol-
low-up, ending with the assessment of histopathological
response). After the end of study participation, patients
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scheme implemented at the NCT Heidelberg. Data on sur-
vival and relapse gathered during this routine follow-up
will be used for the assessment of survival and disease-free
survival for study patients.
Supportive therapy
Proton-pump inhibitors (PPIs) will be given once daily
in standard dosage during the entire preoperative
period.
Premedication with dexamethasone will be performed
according to local standards.
Antiemetic prophylaxis and therapy is recommended
according to local standards.
Granulocyte-Colony Stimulating Factor (G-CSF): In
the case of neutrophils nadir < 0.5 × 10
9/l during the
previous cycle, G-CSF may be administered during the
following cycles according to local standards.
Hydration
During CT and RCT, standard i.v. hydration before and
after cisplatin treatment is mandatory, according to local
rules. Hydration during weekly cisplatin will be done
according to local standards.
PET Imaging
An
18F-FDG PET/CT scan will be performed for each
patient before the initiation of preoperative chemother-
apy (baseline PET) and 14 days after the initiation of
chemotherapy (PET day14). In metabolically non-
responding patients (< 35% SUV decrease), a third PET
scan after initiation of taxan-based chemotherapy and
right before radiochemotherapy (PET1) and a fourth
PET scan after the completion of radiochemotherapy
and immediately before surgery (PET2) will be
performed.
PET scans will be done using a Biograph 6 (Siemens
AG, Erlangen, Germany), axial field of view of 15.4 cm in
3D mode. Patients will fast at least 6 hours before PET
imaging to ensure euglycamic glucose metabolism. Blood
glucose levels are measured before each PET scan. Prior
to each application, patients are advised to rest and con-
tinue to reduce activities for 50 minutes after administra-
tion of 250 to 350 MBq 18F-FDG followed by 500 ml
saline solution to increase the distribution volume.
60 minutes post injection a whole body scan with 3
min/BP from head to upper femur is performed.
The reconstruction of the raw images is performed
after dead time, scatter and random correction using an
iterative method based on the ordered subsets expecta-
tion maximization algorithm (OSEM) of four iterations/
8 subsets, 256 × 256 matrix, Gaussian smoothing and of
3.5 mm transversal slices at full with half maximum.
The image data set is normalized for the injected dose
and the patients body weight, resulting in parametric
imaging using standardized uptake value (SUV) on the
basis of the formula “SUV = tissue concentration (Bq/
g)/(injected dose (Bq)/ body weight (g))”.
The spatial resolution of the reconstructed images is 6
to 8 mm at full width half maximum. For quantitative
evaluation, an automated volume of interest (VOI)
derived from generated regions of interst (ROI) using
the auto3D function within the Syngo Software (Sie-
mens AG, Erlangen, Germany) will be placed over the
tumor in the slice with maximum FDG uptake in the
baseline scan. In the second PET scan, the region of
interest will be placed at the same position as in the
baseline PET as a reference. For patients treated in the
HICON study, the change of FDG-uptake before (PET1)
and after (PET2) radiochemotherapy will be assessed in
relation to the baseline PET.
Figure 1 Trial flow chart.
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surements is used.
Preoperative Radiochemotherapy
The treatment dosage of this radiochemotherapy scheme
is based upon a SAKK study (SAKK 75/02), which purpose
was to investigate the efficacy, toxicity, and feasibility of
preoperative docetaxel-cisplatin together with radiother-
apy. This trimodality treatment showed feasibility in com-
bination with favourable antineoplastic activity and
survival data compared with other trials [17].
After positioning the patient in an adequate custom-
made device a treatment planning CT will be performed.
In all cases a contrast-enhanced CT with a thickness of
3 mm is required. The treatment planning CT scan
should be acquired with the patient in the same position
and using the same immobilization device as for treat-
ment. All tissues receiving irradiation should be included
in the CT scan. A slice by slice segmentation of the target
volume and all organs at risk will be performed. Gross
Tumor Volume (GTV) represents the region judged to
contain gross primary tumor or involved node(s) based
on CT scan and other imaging techniques. The Clinical
Target Volume (CTV) is defined as the GTV plus areas
considered at risk for containing microscopic disease
delineated by the treating physician. CTV represents the
GTV plus a margin of generally 0.2 cm and the nodal
regions receiving elective irradiation. The CTV margins
can be narrower when GTV is in the proximity of the
spinal cord or critical normal tissues. All efforts should
be made to adapt and delineate the CTV according to
the location of the primary tumor and the relative inci-
dence of lymph node involvement in the different ana-
tomic regions of the lymph nodes. Planning Target
Volume (PTV) represents an additional margin of at least
0.2 cm around the CTV to compensate for the variability
of treatment set up and internal organ motion.
The applied total dose is 45 Gy in 25 fractions (1.8 Gy
single dose). Therefore the radio-therapy will be applied
in 5 weeks. For the normal tissue the tolerance doses
(TD 5/5) defined by Emami et al. [18] will be applied.
At least 95% of the CTV should receive 90% of the pre-
scribed total dose and the maximum dose should be
smaller than 110%.
For treatment a linear accelerator with at least 6 MeV
photons will be used. Intensity modulated radiation
therapy (IMRT) is recommended but according to the
treatment protocol also 3-D planned treatment techni-
ques are allowed. The linear accelerator should be
equipped with image guidance (IGRT) and at least
weekly positioning controls will be performed. In case of
severe deviations in the positioning of the patients new
treatment plans should be calculated.
Surgical Therapy
The recommended surgical procedure in patients with
AEG type I is an abdominothoracic oesophagectomy
with intrathoracic anastomosis. In patients with AEG
type II tumors, a transhiatal extended gastrectomy and
an extended D2-lymphadenectomy, including a left ret-
roperitoneal lymphadenectomy can be performed [19].
Histopathologic Analysis
For assessment of histopathologic tumor regression, the
resected primary tumors will be evaluated according to a
recently published scoring system [20]. All patients with
less than 10% residual tumor (regression score 1a and 1b)
will be classified as responders. All other tumors (regres-
sion score 2 and 3) will be classified as nonresponders.
Statistical considerations and sample size estimation
The sample size/power calculations were based on a uni-
variate logistic regression analysis of the predicitveness of
ΔSUV, for histopathological response. The projected sam-
ple size of 25 evaluable patients is sufficient to detect, with
a power of > 80%, an increase of the AUC of the ROC
curve of ΔSUV (with respect to histopathological
response) from 0.5 to 0.8, assuming that the values of
ΔSUV in the groups R and N are represented by indepen-
dent normally distributed variables with equal variances,
and assuming a histopathological response rate of r = 50%
(calculations based on 10000 computer stimulations, a =
10%). While, under the assumptions made above the study
was slightly overpowered (estimated power = 84.7%), the
sample size of n = 25 to some extent safeguards against
the loss of power occurring if r ≠5 0 % ,w i t h ,e . g . ,a ne s t i -
mated power of 80.3% resulting for r = 65%. Assuming a
drop-out rate of about 10% the total number of patients to
be recruited was set at n = 28.
Demographic and other baseline variables, as well as the
treatment-related variables (like, e.g., the number of treat-
ment cycles, dosages, dose modifications) will be analyzed
using frequency tables in case of categorical variables and
summary statistics for quantitative variables. The results of
PET scans will be described by means of summary statis-
tics, box plots, and scatter plots, both overall and for histo-
logical responders and non-responders separately. The
analysis of the primary endpoint will be done using uni-
variate logistic regression with ΔSUV (or a monotone
transform of ΔSUV) as the predictor variable and histolo-
gical response as the outcome variable. In this analysis, the
statistical significance level is set at a =1 0 % .T h ea c c u r a c y
of the binary prediciton rule ΔSUV ≥65% vs.< 65% will be
estimated together with Clopper-Pearson 95% confidence
bounds. Fisher’s exact test will be used to test to compare
the accuracy of this rule with a random prediction. The
association between the difference SUVPET1 and SUVPET2
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tion coefficient and by analyzing the agreement according
t ot h em e t h o dp r o p o s e db yB l a n da n dA l t m a n[ 2 1 ] .T h e
agreement of the results of the aformentioned binary rule
applied to both SUVPET1 and SUVPET2 will be assessed by
means of McNemar’s test. The association between the
difference D12 = SUVPET1-SUVPET2 and histopathological
response will be analyzed by means of the Wilcoxon rank
sum test comparing histopathological responders and
non-responders. A ROC curve for D12 with respect to
response will be produced. The association between
ΔSUV and overall survival as well as disease-free survival
will be assessed using the Cox Proportional Hazard model.
Safety will be analyzed based on adverse evnts and shift
tables for laboratory parameters.
Except for the logistic regression analysis of the primary
endpoint, all analyses are strictly exploratory. For each
particular objective and endpoint, the analysis population
consists of all patients for whom the measurements
required for the analysis are available. Patients having no
PET1-measurement or who drop out before the histo-
pathological response has been determined will be
replaced. No interim analyses will be carried out.
Discussion
The most exciting use of FDG-PET in the management
of localized gastroesophageal cancer is the early assess-
ment of metabolic response during neoadjuvant che-
motherapy. In this indication, early metabolic response
assessment has been shown to contribute to the indivi-
dualization of treatment algorithms; cut-off values have
been prospectively validated and have also been used in
interventional clinical studies [6,8,10,22,23].
As metabolically non-responding patients have poor
survival chances even after R0 resection, the early iden-
tification of these non-responding tumors by FDG-PET
may allow an adaption and optimization of preoperative
treatment. We hypothesize that non-responding patients
after only 2 weeks of chemotherapy might benefit from
a change of the chemotherapy regimen and the addi-
tional use of radiotherapy.
In previous studies, metabolic non-response was asso-
ciated with histopathological non-response [8], however
it remains to be determined if subsequent radioche-
motherapy can transform some metabolic non-respon-
ders after induction chemotherapy into histo-
pathological responders.
While the utility of FDG-PET for early response
assessment has been shown after neoadjuvant che-
motherapy alone, the role of FDG-PET in monitoring
the antitumoral activity of radiochemotherapy has not
been established.
This study was designed to assess the value of meta-
bolic response evaluation before and after initiation of
salvage radiochemotherapy (RCT) in patients with meta-
bolic non-response after 2 weeks of induction che-
motherapy. In order to overcome chemoresistance, the
neo-adjuvant treatment regimen will be intensified by
changing the chemotherapeutic agent and adding radia-
tion treatment.
However, this study is only designed as an imaging/
biomarker study, and further clinical trials are necessary
to eventually answer the question of whether further
neoadjuvant chemotherapy or chemoradiation for
18F-
FDG PET non-responders improves their clinical
outcome.
In this context it still needs to be evaluated whether a
metabolic response fully captures the net effect of treat-
ment on the clinical outcome.
Only randomized trials will ultimately be able to
demonstrate whether treatment regimens with a higher
metabolic response rate also lead to improved patient
survival.
The European Organization of Research and Treat-
ment of Cancer (EORTC) is currently planning a rando-
mized international multicenter trial, comparing the
activity of intensified taxane based RCT to immediate
resection in PET non-responders in terms of histopatho-
logical response and survival.
The HICON study was designed to prospectively eval-
uate if quantitative assessment of tumor metabolism by
FDG-PET is an efficient and clinically useful technique
to monitor tumor response to salvage (radio)-che-
motherapy early in the course of treatment.
In conclusion, this study aims to quantify metabolic
tumor response by determining whether changes in
tumor FDG-uptake, before and after intensified radio-
chemotherapy can predict histopathological response
after completion of neoadjuvant therapy in initially
metabolically non-responding patients.
If it would be possible to early select patients who will
not benefit from intensified salvage radiochemotherapy,
these patients could be spared intensified and potentially
toxic salvage treatments which may impair quality of
life; alternatively, patients could proceed directly to
surgery.
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